Notably, Bromodomain-containing protein 9 (BRD9) is frequently overexpressed in HCC [80], which reportedly upregulates the Wnt/β-catenin [81] and TUFT1/AKT [82] pathways, enhancing tumor aggressiveness and correlating with poorer patient prognosis. This evidence concerns the gene BRD9 and neoplasm.